Cohort C: bevacizumab + Cohort C: placebo
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Respiratory Distress Syndrome (ARDS)
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Trial Timeline
Oct 28, 2025 → Sep 1, 2028
NCT ID
NCT06701656About Cohort C: bevacizumab + Cohort C: placebo
Cohort C: bevacizumab + Cohort C: placebo is a phase 2 stage product being developed by InflaRx for Acute Respiratory Distress Syndrome (ARDS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06701656. Target conditions include Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome).
What happened to similar drugs?
20 of 20 similar drugs in Acute Respiratory Distress Syndrome (ARDS) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06701656 | Phase 2 | Recruiting |
Competing Products
20 competing products in Acute Respiratory Distress Syndrome (ARDS)